Attovia Therapeutics
Yi Zheng is a highly experienced scientist who currently holds the position of Staff Scientist at Attovia Therapeutics since July 2023. Prior to this, Yi Zheng worked as a Senior Scientist at Hengenix Biotech, Inc. and Sr. Scientist at Lakepharma-Curia. With a background in Molecular Biology and Virology, Yi Zheng has a Master of Science from Dalhousie University and a Bachelor of Science from Wuhan University. Yi Zheng's work has led to the approval of multiple products by the US Government, establishing them as an award-winning scientist in the field.
Attovia Therapeutics
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.